Vaccination against chikungunya - a systematic review on the immunogenicity, tolerability, and safety of the live-attenuated vaccine (LAV) Ixchiq and the virus like particle (VLP) vaccine Vimkunya
Vaccine·
- DOI
- 10.1016/j.vaccine.2026.128251
- PMID
- 41564838
- PMCID
- —
- OpenAlex
- W7124901258
- Study type
- Systematic review
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The review identifies two vaccines with strong seroprotection profiles that can complement mosquito protection and vector control for chikungunya prevention, while highlighting the need for ongoing safety monitoring, particularly in older adults.
Structured evidence summary
Research question
The review synthesizes evidence on the immunogenicity, tolerability, and safety of two recently approved chikungunya vaccines, the live-attenuated vaccine Ixchiq and the virus-like particle vaccine Vimkunya, to inform the work of STIKO and DTG.
Study design
Systematic review of phase 3-relevant clinical evidence using PubMed and Embase (OVID), including placebo-controlled randomized controlled trials, cohort, and case-control studies, with risk of bias assessed via the RoB 2-tool and supplemented by post-marketing safety data.
Population and setting
The review focuses on individuals eligible for chikungunya vaccination, including adults aged 12-59 years and those aged 65 years and older, drawing from pivotal trial populations and post-marketing reports.
Main findings
Clinical efficacy data were not available; seroprotection rates were used as a surrogate of protection. Ixchiq achieved seroprotection above 98% after 4 weeks, while Vimkunya reached above 97% in those aged 12-59 years and above 87% in those aged 65 years and older. Both vaccines showed an acceptable safety profile in pivotal studies, but post-marketing data indicated a higher risk of serious adverse events in elderly patients for Ixchiq.
Public-health relevance
The review identifies two vaccines with strong seroprotection profiles that can complement mosquito protection and vector control for chikungunya prevention, while highlighting the need for ongoing safety monitoring, particularly in older adults.
Important limitations
The review relied on seropositivity as a surrogate rather than clinical efficacy outcomes, and no explicit limitations were stated in the abstract. This summary is limited to the supplied single-article abstract and metadata and requires review of the original paper for decision-grade interpretation.
GIDS interpretation
Within the GIDS literature framework, this systematic review provides contextual evidence on the discoverability and appraisal of published phase 3 and post-marketing safety data for recently licensed chikungunya vaccines; it does not link the paper to any live surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 13 auditable classifier relationships to diseases, places, topics, and study design.